The Obstacles to Current Extracellular Vesicle-Mediated Drug Delivery Research
Heedoo Lee, Duo Zhang, Ashish Rai
Affiliation
1Division of Pulmonary and Critical Care Medicine, Department of Medicine, Boston University, Boston, MA, USA
2Internal Medicine, Salem Hospital, North Shore Medical Center, 81 Highland Ave, Salem, MA
#These authors contributed equally to this work
Corresponding Author
Yang Jin, Division of Pulmonary and Critical Care Medicine, Department of Medicine, Boston University, Boston, MA- 02118, USA, Tel: +1-617-414-3298/ Fax: +1-617-536-8093; E-mail: yjin1@bu.edu
Citation
Jin, Y., et al. The Obstacles to Current Extracellular Vesicle-Mediated Drug Delivery Research. (2017) J Pharm Pharmaceutics 4(2): 156- 158.
Copy rights
© 2017 Jin, Y. This is an Open access article distributed under the terms of Creative Commons Attribution 4.0 International License.
Keywords
Abstract
Extracellular Vesicles (EVs) are nanometer-sized cell-derived membrane vesicles that are released by donor cells and play an important role in intercellular communication. In this short communication, we discuss the obstacles currently faced in EV-mediated drug delivery research. The commonly used vehicle for drug delivery in prevalent practice are liposome’s which are synthetic vesicles, these vesicles commonly interact with serum proteins, macrophages and other innate immune response molecules and may be destroyed before they can deliver the drug. EVs however have the same membrane compositions and similar cell surface markers as the cells from which they are derived which thus prevents interactions or provocations of an immune response. In addition, EVs have been used to deliver molecules across tight cellular junctions such as the blood brain barrier. This has led to an interest in using EVs as a novel method for drug delivery. We hereby discuss the potential pitfalls and difficulties that need to be addressed before EVs can be used as drug delivery vehicles in pharmacological research.
